Scynexis, Inc.

Quick facts

Marketed products

• PRA · Infectious Disease
  PRA (prasifungin) is an antifungal agent that inhibits fungal cell wall synthesis by targeting glucan synthase.

Phase 1 pipeline

• [14C]-Ibrexafungerp
• SCY-078 plus DAB
• SCY-078 plus PRA

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Scynexis, Inc. portfolio CI brief
• Scynexis, Inc. pipeline updates RSS